摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

去甲替林 | 72-69-5

中文名称
去甲替林
中文别名
——
英文名称
3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine
英文别名
Nortriptyline;3-(10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-ylidene)-N-methylpropan-1-amine;desmethylamitriptyline;N-methyl-3-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,11,13-hexaenylidene)propan-1-amine
去甲替林化学式
CAS
72-69-5
化学式
C19H21N
mdl
MFCD00242775
分子量
263.382
InChiKey
PHVGLTMQBUFIQQ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    58 °C
  • 沸点:
    396.62°C (rough estimate)
  • 密度:
    0.9790 (rough estimate)
  • 物理描述:
    Solid
  • 溶解度:
    In water, 2.216 mg/L at 25 °C (est)
  • 蒸汽压力:
    2.21X10-6 mm Hg at 25 °C (est)
  • 水溶性:
    -5.5
  • 稳定性/保质期:

    Stable under recommended storage conditions. /Nortriptyline hydrochloride/

  • 分解:
    When heated to decomposition it emits toxic fumes of /nitrogen oxides/.
  • 解离常数:
    pKa = 10.47 (amide) (est)
  • 碰撞截面:
    164.5 Ų [M+H]+ [CCS Type: TW, Method: Major Mix IMS/Tof Calibration Kit (Waters)]
  • 保留指数:
    2209;2208;2212;2215;2215;2215;2217;2217;2220;2220;2220;2220;2220;2222;2222;2225;2227;2227;2227;2240;2191;2180;2191;2200;2202;2174;2215;2202;2211;2240;2214;2210;2207.9;2214;2174;2190;2230;2210;2215.6;2228.9;2212;2215;2215;2215;2234.7

计算性质

  • 辛醇/水分配系数(LogP):
    4.5
  • 重原子数:
    20
  • 可旋转键数:
    3
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.263
  • 拓扑面积:
    12
  • 氢给体数:
    1
  • 氢受体数:
    1

ADMET

代谢
去甲替林通过肝脏的脱甲基和羟基化反应进行代谢,随后与葡萄糖醛酸结合。CYP2D6在去甲替林的代谢中扮演重要角色,CYP1A2、CYP2C19和CYP3A4也有贡献。主要活性代谢物是10-羟基去甲替林,存在顺式和反式两种形式,其中反式形式的效力更高。10-羟基去甲替林是血浆中最常发现的代谢物。大多数其他代谢物都已结合,效力较低。
Nortriptyline is metabolized via demethylation and hydroxylation in the liver followed by glucuronic acid conjugation. CYP2D6 plays a large role in nortriptyline metabolism, with contributions from CYP1A2, CYP2C19 and CYP3A4. The main active metabolite is 10-hydroxynortriptyline exists in both cis and a trans form, with the trans form is higher in potency. 10-hydroxynortriptyline is the most frequently found in the plasma. Most of the other metabolites are conjugated, and are less potent.
来源:DrugBank
代谢
胺碘酮向其脱甲基产物去甲替林在体外的生物转化进行了研究,使用来自四个不同捐赠者的预选人类肝微粒体,以反映一系列的代谢率。反应速度与底物浓度的关系符合S形Vmax模型。Vmax变化从0.42到3.42 nmol/mg/min,Km从33到89 uM胺碘酮酮康唑是对N-脱甲基化高度有效的抑制剂,平均Ki值为0.11 ± 0.013 uM...而奎尼丁(高达50 uM),一种CYP2D6抑制剂,和α-萘黄酮(高达5 uM),仅在低浓度下是CYP1A2抑制剂,没有显示出效果。所有测试的选择性5-羟色胺再摄取抑制剂去甲替林的形成都有抑制作用,其中舍曲林的 平均Ki值为4.37(±3.38)uM,去甲基舍曲林为5.46(±1.95)uM,伏沙明为9.22(±3.69)uM,去甲氟西汀为12.26(±5.67)uM,帕罗西汀为15.76(±5.50)uM,氟西汀为43.55(±18.28)uM。针对大鼠肝CYP3A1的多克隆兔抗体,在抗体/微粒体蛋白比率从1:1变化到10:1时,抑制胺碘酮的N-脱甲基化达到60%的渐近最大值。
Biotransformation of amitriptyline to its demethylated product nortriptyline was studied in vitro with human liver microsomes from four different donors, preselected to reflect a range of metabolic rates. Reaction velocity versus substrate concn was consistent with a sigmoid Vmax model. Vmax varied from 0.42 to 3.42 nmol/mg/min, Km from 33 to 89 uM amitriptyline. Ketoconazole was a highly potent inhibitor of N-demethylation, with a mean Ki value of 0.11 + or - 0.013 uM ... whereas quinidine (up to 50 uM), a CYP2D6 inhibitor, and alpha-naphthoflavone (up to 5 uM), a CYP1A2 inhibitor only at low concn, showed no effect. All selective serotonin reuptake inhibitors tested had an inhibitory effect on the formation of nortriptyline, with mean Ki values of 4.37 (+ or - 3.38) uM for sertraline, 5.46 (+ or - 1.95) uM for desmethylsertraline, 9.22 (+ or - 3.69) uM for fluvoxamine, 12.26 (+ or - 5.67) uM for norfluoxetine, 15.76 (+ or - 5.50) uM for paroxetine, and 43.55 (+ or - 18.28) uM for fluoxetine. A polyclonal rabbit antibody against rat liver CYP3A1, in antibody/microsomal protein ratios varying from 1:1 to 10:1, inhibited N-demethylation of amitriptyline to an asymptotic max of 60%.
来源:Hazardous Substances Data Bank (HSDB)
代谢
抗抑郁药和抗精神病药的代谢特性据报道受到细胞色素P450(CYP)2D6同工酶的显著影响。研究最多的两种抗抑郁药是阿米替林丙米嗪阿米替林转化为去甲替林以及去甲替林代谢为其10-羟基代谢物的过程受到2D6同工酶的影响。
The metabolic disposition of the antidepressants and antipsychotics has been reported to be significantly influenced by the cytochrome P450 (CYP) 2D6 isozyme. The two most studied antidepressants are amitriptyline and imipramine. Amitriptyline conversion to nortriptyline and nortriptyline metabolism to its 10-hydroxymetabolite were shown to be influenced by the 2D6 isozyme.
来源:Hazardous Substances Data Bank (HSDB)
代谢
研究了阿米替林去甲替林地昔帕明丙咪嗪甲醛固定的人肝组织和甲醛溶液中的稳定性。测定了冷冻肝组织中三环类药物及其主要去甲基代谢物的平,并与甲醛固定肝组织和储存肝组织的甲醛溶液中的平进行了比较。显然,在甲醛环境中,次胺去甲替林被甲基化为相应的三胺阿米替林地昔帕明被甲基化为丙咪嗪。在大多数情况下未检测到去甲替林,这表明它可能比地昔帕明降解得更快。冷冻肝组织中药物浓度与甲醛保存组织或甲醛溶液中的浓度之间没有一致的比例。无法量化次胺的甲基化率。在室温下将肝组织储存在甲醛中导致药物渗入甲醛溶液。在甲醛固定的肝组织和甲醛介质中,可以检测到测试的药物长达22个月。
The stability of amitriptyline, nortriptyline, desipramine and imipramine in formalin-fixed human liver tissue and formalin soln was investigated. The levels of the tricyclic and its primary demethylated metabolite in the frozen liver were determined and compared with levels obtained in the formalin-fixed liver and formalin soln in which the liver was stored. It was obvious that some methylation of the secondary amine, nortriptyline, to the corresponding tertiary amine, amitriptyline, and of desipramine to imipramine took place in the formalin environment. Nortriptyline was not detected in most cases, suggesting that it may degrade more rapidly than desipramine. There was no consistent ratio between the concn of the drug in the frozen liver tissue versus formalin-preserved tissue or versus formalin soln. The methylation rates of the secondary amines could not be quantitated. Storage of the liver tissue in formalin at room temp resulted in leaching of the drugs into the formalin soln. The drugs tested may be detected for up to 22 mo in the formalin-fixed liver and in the formalin medium.
来源:Hazardous Substances Data Bank (HSDB)
代谢
去甲替林已知的人类代谢物包括去甲二甲基替林和E-10-羟基去甲替林
Nortriptyline has known human metabolites that include demethylnortriptyline and E-10-hydroxynortriptyline.
来源:NORMAN Suspect List Exchange
毒理性
  • 毒性总结
识别和使用:去甲替林是一种三环类抗抑郁药。人类暴露和毒性:过量/中毒的症状包括以下:心律失常、束支传导阻滞、心脏骤停、低血压、循环衰竭、瞳孔散大、视力模糊、心动过速、血管扩张、尿潴留、胃肠道动力减弱、支气管分泌物减少、干燥的粘膜和皮肤、体温过低、呼吸抑制、癫痫发作、异常肌腱反射、定向障碍、激越、肌阵挛性抽搐、昏迷和锥体束征。一名患有慢性阻塞性肺病的女性在接受去甲替林治疗时,出现了对CO2敏感性降低和通气负荷补偿的抑郁,同时运动耐受性增加,呼吸困难减轻。换句话说,去甲替林显示出对通气控制的抑制作用。去甲替林增加了普通人群中心脏骤停的风险,特别是在存在降低心脏兴奋性的遗传和/或非遗传因素,通过阻断心脏通道的情况下。抗抑郁药在短期研究中增加了儿童、青少年和年轻人自杀思维和行为(自杀倾向)的风险,这些研究针对的是重度抑郁症(MDD)和其他精神疾病。动物研究:口服去甲替林酸盐十二个月的狗能够耐受高达20 mg/kg/日的剂量。然而,大剂量口服(每日40 mg/kg)会导致抑郁和共济失调的症状,并在继续治疗的情况下,在第一个月结束时死亡。在慢性毒性研究中,大鼠能够耐受饮食中相当于150 mg/kg/日的去甲替林酸盐浓度一年。大鼠表现出一些生长迟缓,但没有内脏损伤。使用果蝇黑腹菌的体细胞突变和重组测试(SMART)对去甲替林的遗传毒性进行了测试。在浓度高达100 mM的情况下,该药物没有表现出遗传毒性。
IDENTIFICATION AND USE: Nortriptyline is a tricyclic antidepressant. HUMAN EXPOSURE AND TOXICITY: Symptoms of overdose/poisoning include the following: arrhythmias, bundle branch block, cardiac arrest, hypotension, circulatory collapse, mydriasis, blurred vision, tachycardia, vasodilation, urinary retention, decreased gastrointestinal motility, decreased bronchial secretions, dry mucous membranes and skin, hypothermia, respiratory depression, seizures, abnormal tendon reflexes, disorientation, agitation, myoclonic jerks, coma and pyramidal signs. A woman with chronic obstructive pulmonary disease receiving nortriptyline experienced depression of CO2 sensitivity and ventilatory load compensation with a concomitant increase in exercise tolerance with decreased dyspnea. In other words, nortriptyline demonstrated a depressant effect on ventilatory control. Nortriptyline increases the risk for sudden cardiac arrest in the general population, particularly in the presence of genetic and/or non-genetic factors that decrease cardiac excitability by blocking the cardiac sodium channel. Antidepressant have been shown to increase the risk of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders. ANIMAL STUDIES: Dogs receiving nortriptyline hydrochloride orally for twelve months tolerated as much as 20 mg/kg/day. However, a large oral dose (40 mg per kg daily) caused signs of depression and ataxia and, with continued treatment, death at the end of the first month. In chronic toxicity studies, rats tolerated a concentration of nortriptyline hydrochloride in the diet equivalent to 150 mg/kg/day for one year. Rats showed some growth retardation but no visceral damage. Nortriptyline was tested for genotoxicity using the somatic mutation and recombination test (SMART) in wing cells of Drosophila melanogaster. The drug was not genotoxic at concentrations up to 100 mM.
来源:Hazardous Substances Data Bank (HSDB)
毒理性
  • 毒性总结
据认为,去甲替林要么抑制神经递质血清素在神经元膜上的再摄取,要么作用于β-肾上腺素能受体。三环类抗抑郁药既不抑制单胺氧化酶,也不影响多巴胺的再摄取。
It is believed that nortriptyline either inhibits the reuptake of the neurotransmitter serotonin at the neuronal membrane or acts at beta-adrenergic receptors. Tricyclic antidepressants do not inhibit monoamine oxidase nor do they affect dopamine reuptake.
来源:Toxin and Toxin Target Database (T3DB)
毒理性
  • 肝毒性
肝脏测试异常在接受三环类抗抑郁药治疗的病人中报告发生率高达16%,但升高通常不会超过正常上限的3倍。基转移酶异常通常是轻微的、无症状的,并且是暂时的,即使在继续用药的情况下也会逆转。由于去甲替林导致临床上明显的急性肝损伤的罕见病例已有报道。黄疸的出现通常在使用去甲替林后2到3个月内,且主要的酶模式为肝细胞型。已经描述了几例去甲替林肝毒性的急性实例,这些实例中血清基转移酶平显著升高,并出现了急性肝衰竭。超敏反应和自身免疫的体征和症状通常不出现。
Liver test abnormalities have been reported to occur in up to 16% of patients being treated with tricyclic antidepressants, but elevations are uncommonly above 3 times the upper limit of normal. The aminotransferase abnormalities are usually mild, asymptomatic and transient, reversing even with continuation of medication. Rare instances of clinically apparent acute liver injury have been reported due to nortriptyline. The onset of jaundice is usually within 2 to 3 months of starting nortriptyline and the predominant enzyme pattern has been hepatocellular. Several acute instances of nortriptyline hepatotoxicity with marked elevations in serum aminotransferase levels and acute liver failure have been described. Signs and symptoms of hypersensitivity and autoimmunity are usually not present.
来源:LiverTox
毒理性
  • 药物性肝损伤
药物:去甲替林
Compound:nortriptyline
来源:Drug Induced Liver Injury Rank (DILIrank) Dataset
毒理性
  • 药物性肝损伤
DILI 注解:最令人关注的药物性肝损伤
DILI Annotation:Most-DILI-Concern
来源:Drug Induced Liver Injury Rank (DILIrank) Dataset
吸收、分配和排泄
  • 吸收
去甲替林在胃肠道中被充分吸收,但由于患者的个体差异,血药浓度会有很大的变化。这种药物在首次通过肝脏时就会发生代谢,口服给药后7到8.5小时血药浓度达到峰值。去甲替林生物利用度差异较大,范围在45%到85%之间。
Nortriptyline is readily absorbed in the gastrointestinal tract with extensive variation in plasma levels, depending on the patient. This drug undergoes first-pass metabolism and its plasma concentrations are attained within 7 to 8.5 hours after oral administration. The bioavailability of nortriptyline varies considerably and ranges from 45 to 85%.
来源:DrugBank
吸收、分配和排泄
  • 消除途径
去甲替林及其代谢物主要在尿液中排泄,其中只有很小一部分(2%)的总药物量以未改变的原形药物形式回收。大约三分之一的单次口服剂量在24小时内通过尿液排出。少量药物通过胆汁消除途径在粪便中排泄。
Nortriptyline and its metabolites are mainly excreted in the urine, where only small amounts (2%) of the total drug is recovered as unchanged parent compound. Approximately one-third of a single orally administered dose is excreted in urine within 24 hours. Small amounts are excreted in feces via biliary elimination.
来源:DrugBank
吸收、分配和排泄
  • 分布容积
分布容积(Vd)β,在静脉给药后估计为1633 ± 268升,范围在1460至2030之间(21 ± 4升/千克)。去甲替林可穿过胎盘,并可在母乳中找到。它会分布到心脏、肺、大脑和肝脏。
The apparent volume of distribution (Vd)β, estimated after intravenous administration is 1633 ± 268 L within the range of 1460 to 2030 (21 ± 4 L/kg). Nortriptyline crosses the placenta and is found in the breast milk. It distributes to the heart, lungs, brain, and the liver.
来源:DrugBank
吸收、分配和排泄
  • 清除
在一项对健康志愿者的研究中,去甲替林的的平均血浆清除率为54升/小时。去甲替林的平均系统清除率为30.6 ± 6.9升/小时,范围在18.6到39.6升/小时之间。
The average plasma clearance of nortriptyline in a study of healthy volunteers was 54 L/h. The average systemic clearance of nortriptyline is 30.6 ± 6.9 L / h, within the range of 18.6 to 39.6 L/hour.
来源:DrugBank
吸收、分配和排泄
/MILK/ 去甲替林会分布到乳汁中。乳汁中的去甲替林浓度似乎与或略高于母体血清中的浓度。
/MILK/ Nortriptyline is distributed into milk. Nortriptyline concentrations in milk appear to be similar to or slightly greater than those present in maternal serum.
来源:Hazardous Substances Data Bank (HSDB)

安全信息

  • 海关编码:
    2921499090
  • 储存条件:
    2-8°C

SDS

SDS:bd48696ba98d62a6ab0f10c022be4dad
查看

制备方法与用途

去甲替林(去甲基阿米替林)是阿米替林的主要活性代谢产物,属于三环类抗抑郁药,主要用于缓解抑郁症症状。研究显示,去甲替林也是一种有效的自噬抑制剂

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量
    • 1
    • 2

反应信息

  • 作为反应物:
    描述:
    去甲替林 在 CYP2C19 作用下, 生成 去甲基去甲替林
    参考文献:
    名称:
    血清样品中醌类化合物的推导同时测定阿米替林和去甲替林的新方法
    摘要:
    通过磁性固相萃取(MSPE)和分光光度法联合测定两种三环抗抑郁药(TCA)[阿米替林(AT)及其主要代谢物(去甲替林; NT)]的新颖有效策略建议。为此,使用咪唑鎓离子液体(Imz)改性的Fe 3 O 4 @SiO 2纳米颗粒(Fe 3 O 4 @SiO 2-Imz)用作MSPE的吸附剂。在优化条件下进行了预浓缩(负载-解吸)研究,包括pH,吸附剂量,接触时间,洗脱液体积和解吸时间。之后,通过特定策略确定每种药物。乙醛(AC)和2,3,5,6-四氯-1,4-苯醌(氯腈; CL)用作与NT反应的化学试剂,而AT不与这些试剂反应。该方法基于NT的仲胺基和AC之间的缩合反应,得到烯胺,随后与CL反应,生成氯化醌取代的烯胺。最终产物在556 nm处显示出最大吸收,而AT在240 nm处测定。血清样品中NT和AT的检出限(LOD)为0.19和0。− 1。NT和AT的定量限(LOQs)分别为0.63和2
    DOI:
    10.1016/j.saa.2016.06.013
  • 作为产物:
    描述:
    阿米替林 在 CYP2C19 作用下, 生成 去甲替林
    参考文献:
    名称:
    血清样品中醌类化合物的推导同时测定阿米替林和去甲替林的新方法
    摘要:
    通过磁性固相萃取(MSPE)和分光光度法联合测定两种三环抗抑郁药(TCA)[阿米替林(AT)及其主要代谢物(去甲替林; NT)]的新颖有效策略建议。为此,使用咪唑鎓离子液体(Imz)改性的Fe 3 O 4 @SiO 2纳米颗粒(Fe 3 O 4 @SiO 2-Imz)用作MSPE的吸附剂。在优化条件下进行了预浓缩(负载-解吸)研究,包括pH,吸附剂量,接触时间,洗脱液体积和解吸时间。之后,通过特定策略确定每种药物。乙醛(AC)和2,3,5,6-四氯-1,4-苯醌(氯腈; CL)用作与NT反应的化学试剂,而AT不与这些试剂反应。该方法基于NT的仲胺基和AC之间的缩合反应,得到烯胺,随后与CL反应,生成氯化醌取代的烯胺。最终产物在556 nm处显示出最大吸收,而AT在240 nm处测定。血清样品中NT和AT的检出限(LOD)为0.19和0。− 1。NT和AT的定量限(LOQs)分别为0.63和2
    DOI:
    10.1016/j.saa.2016.06.013
  • 作为试剂:
    描述:
    4-methyl-N-(oxiran-2-ylmethyl)benzenesulfonamide二氯甲烷去甲替林potassium carbonate三苯基膦偶氮二甲酸二乙酯 作用下, 以 N-甲基吡咯烷酮甲苯 为溶剂, 反应 12.5h, 生成 5-(chloromethyl)-3-tosylthiazolidine-2-thione
    参考文献:
    名称:
    通过碱促进环氧磺酰胺和杂枯草碱的环化反应 合成噻唑烷-硫酮,亚氨基噻唑烷和恶唑烷†
    摘要:
    环氧磺酰胺在碱的存在下与杂聚枯烯(二硫化碳/异硫氰酸酯/异氰酸酯)反应,以良好的收率和高收率提供极好的区域选择性的扩环产物。N-(2-溴乙基) -磺酰胺也可以用作底物。该反应通过5 -exo-tet途径进行,而没有形成氮丙啶中间体。
    DOI:
    10.1039/c7ob02915b
点击查看最新优质反应信息

文献信息

  • [EN] COMPOUNDS AND THEIR USE AS BACE INHIBITORS<br/>[FR] COMPOSÉS ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE BACE
    申请人:ASTRAZENECA AB
    公开号:WO2016055858A1
    公开(公告)日:2016-04-14
    The present application relates to compounds of formula (I), (la), or (lb) and their pharmaceutical compositions/preparations. This application further relates to methods of treating or preventing Αβ-related pathologies such as Down's syndrome, β- amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI ("mild cognitive impairment"), Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia, including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease.
    本申请涉及式(I)、(Ia)或(Ib)的化合物及其药物组合物/制剂。本申请进一步涉及治疗或预防与Αβ相关的病理学,如唐氏综合症,β-淀粉样蛋白血管病,如但不限于脑淀粉样蛋白血管病或遗传性脑出血,与认知损害相关的疾病,如但不限于MCI(“轻度认知损害”),阿尔茨海默病,记忆丧失,与阿尔茨海默病相关的注意力缺陷症状,与疾病如阿尔茨海默病或痴呆症相关的神经退行性疾病,包括混合性血管性和退行性起源的痴呆,早老性痴呆,老年性痴呆和与帕森病相关的痴呆的方法。
  • [EN] METHYL OXAZOLE OREXIN RECEPTOR ANTAGONISTS<br/>[FR] MÉTHYLOXAZOLES ANTAGONISTES DU RÉCEPTEUR DE L'OREXINE
    申请人:MERCK SHARP & DOHME
    公开号:WO2016089721A1
    公开(公告)日:2016-06-09
    The present invention is directed to methyl oxazole compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.
    本发明涉及甲基噁唑化合物,其为促进睡眠的受体拮抗剂。本发明还涉及所述化合物在潜在治疗或预防涉及促进睡眠的神经和精神疾病和疾病中的用途。本发明还涉及包含这些化合物的组合物。本发明还涉及这些组合物在潜在预防或治疗涉及促进睡眠的疾病中的用途。
  • 4' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY
    申请人:Dunn Robert
    公开号:US20080318941A1
    公开(公告)日:2008-12-25
    The present disclosure provides compounds having affinity for the 5-HT 6 receptor which are of the formula (I): wherein R 1 , R 2 , R 5 , R 6 , B, D, E, G, Q, x and n are as defined herein. The disclosure also relates to methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.
    本公开提供了具有亲和力的化合物,其对5-HT 6 受体具有亲和力,其化学式为(I): 其中R1、R2、R5、R6、B、D、E、G、Q、x和n如本文所定义。本公开还涉及制备这种化合物的方法、含有这种化合物的组合物以及使用这些化合物的方法。
  • HETEROBICYCLIC COMPOUNDS
    申请人:Amgen Inc.
    公开号:US20130225552A1
    公开(公告)日:2013-08-29
    Heterobicyclic compounds of Formula (I): or a pharmaceutically-acceptable salt, tautomer, or stereoisomer thereof, as defined in the specification, and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, Huntington's Disease, and the like.
    Formula (I)的杂环化合物: 或其药用可接受的盐、互变异构体或立体异构体,如规范中所定义,并含有它们的组合物,以及制备这种化合物的方法。本文还提供了通过抑制PDE10来治疗由此可治疗的疾病或疾病的方法,如肥胖症、非胰岛素依赖型糖尿病、精神分裂症、躁郁症、强迫症、亨廷顿病等。
  • NAPHTHALENE-BASED INHIBITORS OF ANTI-APOPTOTIC PROTEINS
    申请人:Pellecchia Maurizio
    公开号:US20090105319A1
    公开(公告)日:2009-04-23
    Methods of using apogossypol and its derivatives for treating inflammation is disclosed. Also, there is described a group of compounds having structure A, or a pharmaceutically acceptable salt, hydrate, N-oxide, or solvate thereof are provided: wherein each R is independently selected from the group consisting of H, C(O)X, C(O)NHX, NH(CO)X, SO 2 NHX, and NHSO 2 X, wherein X is selected from the group consisting of an alkyl, a substituted alkyl, an aryl, a substituted aryl, an alkylaryl, and a heterocycle. Compounds of group A may be used for treating various diseases or disorders, such as cancer.
    使用阿波戈司宝及其衍生物治疗炎症的方法被披露。此外,还描述了一组具有结构A的化合物,或其药学上可接受的盐、合物、N-氧化物或溶剂化合物: 其中每个R独立地选自H、C(O)X、C(O)NHX、NH(CO)X、SO2NHX和NHSO2X组成的组,其中X选自烷基、取代烷基、芳基、取代芳基、烷基芳基和杂环的组。A组化合物可用于治疗各种疾病或疾病,如癌症。
查看更多

表征谱图

  • 氢谱
    1HNMR
  • 质谱
    MS
  • 碳谱
    13CNMR
  • 红外
    IR
  • 拉曼
    Raman
查看更多图谱数据,请前往“摩熵化学”平台
mass
查看更多图谱数据,请前往“摩熵化学”平台
查看更多图谱数据,请前往“摩熵化学”平台
查看更多图谱数据,请前往“摩熵化学”平台
  • 峰位数据
  • 峰位匹配
  • 表征信息
Shift(ppm)
Intensity
查看更多图谱数据,请前往“摩熵化学”平台
Assign
Shift(ppm)
查看更多图谱数据,请前往“摩熵化学”平台
测试频率
样品用量
溶剂
溶剂用量
查看更多图谱数据,请前往“摩熵化学”平台